| Title | Recombinant Insulin-Like Growth Factor (IGF)-I Treatment in Short Children with Low IGF-I Levels: First-Year Results from a Randomized Clinical Trial. | | Author(s) | Midyett LK, Rogol AD, Van Meter QL, Frane J, Bright GM, on behalf of the MS301 Study Group | | Institution | Pediatrics (L.K.M.), Children's Mercy Hospital, Kansas City, Missouri 64108; Pediatrics (A.D.R.), University of Virginia, Charlottesville, Virginia 22908; Pediatrics (A.D.R.), Riley Hospital for Children, Indianapolis, Indiana 46202; Peachtree City (Q.L.V.M.), Georgia 30269; Santa Monica (J.F.), California 90403; and Tercica, Inc., a subsidiary of the Ipsen Group (G.M.B.), Brisbane, California 94005. | | Source | J Clin Endocrinol Metab 2009 Oct 30. | | Abstract | Context: Short stature in children may be associated with low IGF-I despite normal stimulated GH levels and without other causes.
Objective: Our objective was to assess the safety and efficacy of recombinant human IGF-I (rhIGF-I) in short children with low IGF-I levels.
Design: This was a 1-yr, randomized, open-label trial (MS301).
Setting: The study was conducted at 30 U.S. pediatric endocrinology clinics.
Subjects: A total of 136 short, prepubertal subjects with low IGF-I (height and IGF-I SD scores <-2, stimulated GH >/=7 ng/ml); 124 completed the study, and six withdrew for adverse events and six for other reasons. Intervention: rhIGF-I was administered sc, twice daily using weight-based dosing (40, 80, or 120 mug/kg; n = 111) or subjects were observed (n = 25). Main Outcome Measures: First-year height velocity (centimeters per year, cm/yr), height SD score, IGF-I, and adverse events were prespecified outcomes.
Results: First-year height velocities for subjects completing the trial were increased for the 80- and 120-mug/kg twice-daily vs. the untreated group (7.0 +/- 1.0, 7.9 +/- 1.4, and 5.2 +/- 1.0 cm/yr, respectively; all P < 0.0001) and for the 120- vs. 80-mug/kg group (P = 0.0002) and were inversely related to age. They were not predicted by GH stimulation or IGF-I generation test results and were not correlated with IGF-I antibody status. The most commonly reported adverse events of special interest during treatment were headache (38% of subjects), vomiting (25%), and hypoglycemia (14%).
Conclusions: rhIGF-I treatment was associated with age- and dose-dependent increases in first-year height velocity. Adverse events during treatment were less common than in previous studies and were generally transient, easily managed, and without known sequelae. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19880790 |
|
